Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration

Transcription

1 Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration

2 Follow the protocol and IDE regulations to ensure data integrity (21 CFR Part 812) Protect your human subjects (21 CFR Part 50) Disclose your financial interests (21 CFR Part 54)

3 A comprehensive, agency-wide program of on-site inspections and data audits designed to monitor all aspects of the conduct and reporting of FDA-regulated research

4 Protect the rights, safety, and welfare of human research subjects Assure the quality, reliability, and integrity of data collected

5 Clinical Investigators Sponsors, Contract Research Organizations, and Monitors Institutional Review Boards Good Laboratory Practices

6 New product or indication Premarket approval (PMA) or notification (510(k)) New technology Investigational device exemption (IDE) Complaints Allegations of research misconduct Non-compliant history Previously violative (OAI) inspection Routine surveillance Institutional Review Boards

7

8

9 No Action Indicated (NAI) No objectionable conditions or practices Voluntary Action Indicated (VAI) Objectionable conditions or practices But not at threshold to take or recommend administrative or regulatory action Official Action Indicated (OAI) Serious objectionable conditions found Regulatory action recommended

10

11 NFC = No For Cause inspections included

12

13

14

15

16 CDRH BIMO Warning Letters 2006 to 2010

17 CDRH BIMO Warning Letters

18 Recidivist OAIs across program areas: CI = 38% S/M = 21% IRB = 31% GLP = 10% N = 144

19

20 N = 365

21

22

23 General Responsibilities of Investigators (21 CFR ) Ensure that the investigation is conducted according to the signed agreement, the investigational plan and applicable FDA regulations. Protect the rights, safety, and welfare of subjects under the investigator's care. Control devices under investigation. Ensure that informed consent is obtained from each subject in accordance with (21 CFR Part 50)

24 Specific Responsibilities of Investigators (21 CFR ) 1. Await IRB approval and any necessary FDA approval before obtaining written informed consent or permitting subject participation. 2. Use investigational devices only on subjects enrolled in the study 3. Financial disclosure. 4. Dispose of the device properly.

25

26

27 Inspections (21 CFR ) Investigators are required to permit FDA to inspect and copy any records pertaining to the investigation including, in certain situations, those which identify subjects.

28 Investigational Device Distribution and Tracking The IDE regulations prohibit an investigator from providing an investigational device to any person not authorized to receive it (21 CFR (c)). Monitor the shipping, use, and final disposal of the devices with good record keeping practices. Return any remaining supply of the device or otherwise to dispose of the device as the sponsor directs (21 CFR (e)).

29 Prohibition of Promotion and Other Practices (21 CFR 812.7) The IDE regulations prohibit the promotion and commercialization of a device that has not been first cleared or approved for marketing by FDA. Including: Promotion or test marketing of the investigational device Charging subjects or investigators for the device a price larger than is necessary to recover the costs of manufacture, research, development, and handling Unduly prolonging an investigation beyond the point needed to collect data required to determine whether the device is safe and effective Representing that the device is safe or effective for the purposes for which it is being investigated.

30 Annual Progress Reports and Final Reports The IDE regulations do not specify the content of the annual progress or final reports. Check with your IRB what information they need. Consider the following information: IDE number Device name & Indications for use Brief summary of study progress in relation to investigational plan Number of subjects enrolled Number of devices received, used, and the final disposition of unused devices Brief summary of results and conclusions Summary of anticipated and unanticipated adverse device effects Description of any deviations from investigational plan Reprints of any articles you ve published

31

32 Investigator s detailed report Sent to the center that issued the inspection Evidence accompanies report Center classifies the inspection and determines outcome (OAI, VAI, NAI)

33 No Action Indicated (NAI) No objectionable conditions or practices Voluntary Action Indicated (VAI) Objectionable conditions or practices But not at threshold to take or recommend administrative or regulatory action Official Action Indicated (OAI) Serious objectionable conditions found Regulatory action recommended

34 Submit a prompt written response Assess the root cause of the problem Evaluate the extent of the problem Explain actions to correct the problem Implement preventative actions to avoid recurrence Timelines for implementation Supporting documentation

35 Rejection of data IRB restrictions Deficiency letter IDE, 510(k), or PMA withdrawal No new studies or subjects Application Integrity Policy Untitled letters Civil Money Penalties Warning letters Seizure / Detention Consent Agreement Injunction Disqualification Criminal Prosecution CI, IRB, GLP Debarment

36 Did not follow investigational plan and FDA regs Did not follow signed investigator agreement Inadequate documentation of case history/ device exposure Did not properly obtain informed consent Inadequate record of protocol and/or protocol deviations

37 Review the protocol can you realistically follow it at your site? Select qualified study personnel & ensure training Ensure the protection of your human subjects Ensure data integrity Mitigate bias

38

39 You initiate and actually conduct, alone or with others, an investigation The device is administered, dispensed, or used under your direction

40 General Duties Submit the IDE application to FDA Obtain both FDA and IRB approval for the investigation Select qualified investigators and provide them with the information they need to conduct the investigation properly Ensure proper monitoring of the investigation Ensure that any reviewing IRB and FDA are promptly informed of significant new information about an investigation

41 Selection of Investigators (21 CFR ) Selecting qualified investigators (training and experience) Shipping the investigational device only to participating investigators Obtaining a signed investigator's agreement from each investigator. Selecting qualified monitors (training and experience) Providing investigators with the investigational plan and report of prior investigations of the device. (21 CFR )

42 Monitoring (21 CFR ) Securing compliance of all investigators Evaluating all unanticipated adverse device effects Resuming terminated investigations

43 Monitoring Visits Monitors review records such as: IRB approvals Informed Consent Documents Source documents Case Report Forms (CRF)

44 Controlling Distribution and Disposition of Devices May ship investigational devices only to qualified investigators participating in the clinical investigation ( (b)). Must maintain complete, current, and accurate records pertaining to the shipment and disposition of the investigational device ( (b)(2)). Instruct investigators on their recordkeeping obligations and requirments ( (a)).

45 Prohibition of Promotion and Other Practices (21 CFR 812.7)

46 Supplemental Applications (21 CFR (a) and (b)) Changes in the investigational plan Addition of new institutions

47 Records Investigator Sponsor All Correspondence Pertaining to the Investigation X X Shipment, Receipt, Disposition X X Device Administration and Use X - Subject Case Histories X - Informed Consent X - Protocols and Reasons for Deviations from Protocol X - Adverse Device Effects and Complaints X X Signed Investigator Agreements - X Membership/Employment/Conflicts of Interest - X

48 Type of Report Prepared by Investigators for: Prepared by Sponsors for: Unanticipated Adverse Effect Evaluation Sponsors and IRBs FDA, IRBs and Investigators Withdrawal of IDE Approval Sponsors FDA, IRBs and Investigators Progress Report Sponsors, Monitors and IRBs FDA and IRBs Final Report Sponsors and IRBs FDA, IRBs and Investigators Emergencies (Protocol Deviations) Sponsors and IRBs FDA Inability to Obtain Informed Consent Sponsors and IRBs FDA Withdrawal of FDA Approval N/A IRBs and Investigators Current Investigator List N/A FDA Recall and Device Disposition N/A FDA and IRBs Records Maintenance Transfer Sponsors FDA Significant Risk Determinations N/A FDA

49 Inspections (21 CFR ) Sponsors are required to permit FDA to enter and inspect (at reasonable times and in a reasonable manner) any establishment where devices are held (including any establishment where devices are manufactured, processed, packed, installed, used, or implanted or where records or results from use of devices are kept). FDA may also inspect and copy all records relating to an investigation including, in certain situations, records which identify subjects.

50 Did not ensure proper monitoring Inaccurate or incomplete correspondence Inadequate or no records of device shipment/disposition Did not obtain signed investigator agreement Did not inform investigators Did not secure investigator compliance Inadequate record retention Inadequate or no progress reports

51 Remember Correct issues before they jeopardize the study or subject safety Minimize recurring issues Practice protocol care Create an accountable organizational culture Focus on good ethics and research practices Protect your reputation Protect your subjects

52 CDRH Homepage CDRH Learn Device Advice Disqualification List